Materials and Methods: 64 patients with FG, who were followed up and treated at the Urology clinic of University Hospital between January 2011 and July 2020, were included in the study. Patients were divided into two groups: While group 1 received CWD treatment, group 2 received NPWT. Demographic characteristics, etiology, length of stay, number of debridements, additional surgeries, Fournier Gangrene Severity Index (FGSI) scores, analgesic needs, area of necrosis and amount of involvement of the patients were retrospectively analyzed.
Results: 37 patients in group 1 and 27 patients in group 2 were included in the study. All patients were male. The mean hospital stay was 17.9 ± 1.8 days in group 1, while it was 12.7 ± 1.1 days in group 2 (p:0.91). The mean debridement numbers in Group 1 and Group 2 were 7.1 ± 0.8 and 3.7 ± 0.3, respectively (p:0.004). The mean number of daily analgesic use in Group 1 and Group 2 was 2.4 ± 0.12 and 1.44 ± 0.08, respectively (p<0.001). The mean area of necrosis was 124 ± 11.3 cm2 and 147 ± 18.1 cm2, respectively (p:0.614). In group 1 and group 2, 4 and 2 patients died, respectively (p:1.00).
Conclusion: NPWT reduced the treatment burden of this disease by reducing the number of debridements and analgesic use. However, NPWT did not reduce the length of hospital stay.
FG mostly develops in patients with comorbidities; however, it can also occur in patients without comorbidities. Hypertension, obesity (BMI>30 kg/m2), congestive heart failure, tobacco use, immunosuppressive conditions (such as acquired immun deficiency syndrome [AIDS]), peripheral vascular diseases and alcoholism have been found to be associated with an increased risk in FG [2]. Diseases and risk factors in the etiology for FG help inoculation of microorganisms by damaging the immune system. Polymicrobial agents, as in many necrotizing soft tissue infections, cause FG. Microorganisms normally found in the perineum and genital area cause infection after a suitable environment is created. The cornerstones of FG treatment are immediate debridement of all necrotic tissues, initiation of broad-spectrum antibiotics, and patient stabilization with hemodynamic resuscitation [3]. FG is accepted as one of the urological emergencies because the rate of spread of facial necrosis can be 2-3 cm/hour. In addition, the fact that up to 21% of patients present with hypotension and septic shock increase the importance of patient stabilization before emergency surgery [4].
Broad-spectrum antibiotherapy should be started empirically as soon as FG is diagnosed, and then revised according to culture results [5]. Initial antibiotherapy should target common bacteria such as staphylococcus and streptococcal species, gram-negative bacteria, clostridium, bacteroides and pseudomonas [6]. In patients with a history of fungal infection or in immunosuppressed patients, antifungals such as amphotericin B or fluoroquinolones should be added to the treatment, considering fungal infection as the causative agent [7]. However, due to poor vascularization in fascial tissues, surgical intervention is key for an effective antibiotic therapy.
Early debridement of necrotic and dead tissue is a critical step in controlling the infection. Debridement of all dead tissues in the first operation is considered the most important factor in the patient"s survival [8]. Extensive debridement and ventilation of living tissues by opening windows are recommended. Close monitoring of the wound and repeated debridements are necessary to control infection [9].
While FG can also be treated with classical dressing, vacuumassisted closure (VAC) therapy has become popular in recent years [10]. VAC method accelerates wound healing by reducing edema and increasing blood flow. VAC system increases angiogenesis and improves tissue nutrition and formation. The main mechanism of the device is that VAC system drains dirty liquid and stagnant debris [6].
In this study, the effect of VAC therapy for the treatment of FG and the factors affecting this disease tried to be shown.
Figure 1. Scrotal swelling, necrosis and erythema in a patient with Fournier's Gangrene
Figure 2. Vital tissues after surgical debridements
Figure 3. Vacuum device placement after surgery
Statistical Analysis
In the comparison of two independent groups, t test was
used to see if the results were in a normal distribution and Mann
Whitney U test was used to find out if it did not. Chi-square
or fisher"s exact tests were used for the analysis of qualitative
data. Quantitative data was expressed as mean ± std values in
the tables. Categorical data were written as n (frequency) and
percentages (%). The data was analyzed at 95% confidence level
and the P value was considered significant when it was less then
0.05.
Table 1. Number of patients and comorbidities by groups
FG is basically divided into 3 groups according to its etiology. The group of patients whose etiology cannot be found is called idiopathic. In our study, in group 1, 21 (56.8%) patients had urogenital origin, 7 (18.8%) patients had anorectal origin, 3 (8.7%) patients had skin infection and 6 (16.2%) patients were idiopathic. In group 2, 16 (59.3%) patients had urogenital origin, 9 (33.3%) patients had anorectal origin, 1 (3.7%) patient had skin infection and 1 (3.7%) patient was idiopathic. There was no statistical difference between the groups according to their etiology (p>0.05) (Table 2).
Table 2. Distribution of patients by etiology
The mean hospital stay was 17.9 ± 1.8 and 12.7 ± 1.1 days, for group 1 and group 2, respectively (p:0.91). The mean debridement numbers were 7.1 ± 0.8 and 3.7 ± 0.3, respectively (p:0.004). The mean number of daily analgesic use was 2.4 ± 0.12 and 1.44 ± 0.08, respectively (p<0.001). The mean area of necrosis was 124 ± 11.3 cm2 and 147 ± 18.1 cm2, respectively (p:0.614). In group 1, orchiectomy was performed on 8 patients, 3 patients bilaterally and 5 patients unilaterally. In Group 2, a total of 8 patients underwent unilateral orchiectomy (p: 0.465). In addition, colostomy was performed on 4 patients in group 1, penectomy on 1 patient, colostomy on 5 patients in group 2, and cystostomy on 2 patients (p> 0.05). The wounds of 14 patients in group 1 and 16 patients in group 2 were closed primarily. The wounds of 19 patients from group 1 and 9 patients from group 2 were closed after reconstruction by the plastic surgery department (p:0.103). The mean FGSI scores in group 1 and 2 were 4.6 ± 0.5 and 3.8 ± 0.6, respectively (p:0.227). In group 1 and 2, 4 and 2 patients died, respectively (p:1.00) (Table 3).
Table 3. Patient characteristics and additional surgeries
All patients included in the study had scrotal involvement. Inguinal region involvement was 17 (45.9%) and 13 (48.1%) in group 1 and 2, respectively (p:0.862). Perineal involvement was 20 (54.1%) and 13 (48.1%) in group 1 and 2, respectively (p:0.641). Abdominal spread was 3 (8.1%) and 4 (14.8%) in group 1 and 2, respectively (p:0.443). Penile involvement was 2 (5.4%) and 4 (14.8%) in group 1 and 2, respectively. In group 1 and 2, spread to the thigh region was 2 (5.4%) and 5 (18.5%), respectively (Table 4).
Table 4. Distribution according to the areas of necrosis involved
A total of 6 patients who participated in the study are deceased. The mean FGSI score of the surviving patients, whom we mentioned in Table 5 as survivor, was 3.4 ± 0.3. The mean FGSI score of the patients who deceased, whom we defined as non-survivors, was 12.5 ± 1. A statistical difference was found between them (p<0.001) (Table 5).
NPWT was described by Argenta and Morykwas in 1997 [8]. Then it was used for the first time in FG treatment by Weinfeld et al [12]. This technique transforms an open wound into a temporarily closed and controllable environment. In laboratory and clinical studies, it has been shown that the use of a VAC device increases blood flow and creates a suitable environment for wound healing [13]. There are different opinions about whether NPWT shortens the hospitalization time in patients with FG. In their study, Assenza et al., reported that NPWT treatment shortens the hospitalization time and leads to an early reconstructive surgery [14]. In a study by Czymek et al., it was found that NPWT prolongs the length of stay compared to the CWD method [15]. However, in the study of Yanaral et al., no difference was found between CWD and NPWT applied groups in terms of hospitalization length [16].
In our study, there was a decrease in the number of debridements and daily average analgesic use in NPWT applied group compared to CWD group. With a decrease in the use of analgesics, the number of complications associated with the use of these drugs also decreased. The scarcity of analgesic use indicates that patients comfort has increased and their pain has also decreased. In addition, this comfort causes NPWT to be preferred not only by patients but also by physicians. As the number of debridements decreases, the physician spends less time and the patients complain less about pain. These factors are some of the reasons why most physicians prefer NPWT. In a study conducted by Ozturk et al., it was shown that 92% of physicians prefer NPWT in the treatment and management of FG [17]. It is seen that the high mortality rate has decreased with improvement in health services, better definition of the treatment algorithm of the disease and technological advances. In our study, mortality rates were 10.8% with 4 patients and 7.4% with 2 patients in CWD group and NPWT group, respectively. The total number of patients, who deceased, is 6 and this rate is 9.4%. Considering that FG disease progresses with high mortality, our result was lower than the literature [18]. We attribute this to the fact that our hospital is centrally located therefore easily accessible, and that we work with a serious team approach, which does not delay the urgent surgery of these patients.
Urinary and fecal diversion are essential in the management of FG disease. For FG, which often involves the scrotum and perineum, contamination of the wound with urine or feces will delay wound healing. Urethral catheterization and cystostomy catheter are among the options for urinary diversion. Although it has been stated by a small number of researchers that cystostomy can be applied to all patients, and urethral catheterization is often sufficient [19]. In Ghnnam"s series of 74 patients published in 2008, all patients except one with urethral injury received a urethral catheter and it was sufficient for urinary diversion [20]. In our series of 64 patients, a single cystostomy catheter was applied to 2 patients, which is compatible with the literature. Although cystostomy catheter application is a minimally invasive procedure, it is still a surgical procedure that may have complications. In our opinion, a cystostomy catheter is not required for all patients; a cystostomy catheter is required only in cases of necrosis involving the penis and urethra. The issue of fecal diversion is controversial in the treatment management of FG. Some researchers recommend routine fecal diversion to reduce wound contamination and speed healing [21]. Diversion colostomy is recommended in cases of anal sphincter involvement, in order to eliminate fecal incontinence and fecal contamination risk of the wound. In the study conducted by Chen et al., it was shown that primary diversion colostomy reduces the risk of mortality compared to secondary colostomy [22]. However, this issue raises doubts because it is not correlated with the place where the disease first reached. In a retrospective study by Korkut et al., the mortality rate was 7% in the group that did not require a stoma, while it was 38% in the group that required a stoma [23]. In another study by Kızılay et al., the necessity of peroperative colostomy was reported as a risk factor that increases mortality in multivariate analysis. In this research article, it is stated that colostomy application is a result rather than a cause in showing mortality, and that this alone is an important factor showing the prevalence and severity of the disease [24]. As an alternative to diversion colostomy, a fecal management system has been described. This method protects the wound from fecal contamination, such as a colostomy [25]. In the study conducted by Estrada et al., it was stated that the fecal management system is an effective method for fecal diversion and is an alternative to colostomy [26]. With this device, stoma-related complications are eliminated, it also provides better psychological recovery for the patient and is more economical. Fecal management system contraindications; rectal neoplasm, penetrating rectal injuries and fistulas. In our study, protective colostomy was performed on a total of 9 patients, 4 patients in CWD group and 5 patients in NPWT group. Fecal management system was applied to patients with extensive perineal involvement. A colostomy was performed in 2 of the 6 patients who deceased.
Although it is stated that the blood supply of the testicles originates from the retroperitoneum and therefore will be preserved in FG, it is a known fact that it goes to necrosis, especially in late cases. In a study by Morua et al., orchiectomy was performed in 18% of patients [27]. In our study, orchiectomy was performed on a total of 16 patients (25%), 3 of whom were bilateral. In our study, we attribute this high rate to the higher rate of urogenital causes in etiology. Bilateral orchiectomy and penectomy were performed on a patient diagnosed with prostate cancer in CWD group. This is the only patient for whom we performed penectomy. Unfortunately, this patient died on the first postoperative day.
FGSI scoring system was developed in 1995 by Laor et al. In this scoring, when the cut-off value is taken as 9, it is stated that the mortality probability is 75% for the values above it, and probability of survival is 78% for the values below 9 [28]. In a study by Corcoran et al., a statistically significant difference was found between the average FGSI score of the living and the average FGSI score of the deceased as 5.3 and 10.9, respectively [29]. In a recent study by Kutsal et al., it was shown that NPWT causes significant decrease in 1st week"s FGSI mean score. But mortality assessment wasn"t evaluated in their study [30]. We evaluated FGSI scores during the first day of patients" hospitalization. In our study, the higher score in FGSI was correlated with the increased risk of mortality.
Another important issue concerning with NPWT is cost. The seemingly expensive VAC device is at par with the CWD method as it reduces the number of debridements and the need for analgesics. It has been stated by some researchers in the literature that NPWT is not more expensive yet even cheaper than CWD method [31].
The shortcomings of our study are that it is retrospective, and that no cost analysis was performed. Despite all its advantages, NPWT should not be used in all cases such as malignant tissues, exposed vessels, nerves, organs and anastomoses, untreated osteomyelitis, non-enteric or unexplained fistulas. In addition, it should not be used in cases with high bleeding risk and in cases where infective tissues are not fully debrided [32]. It is imperative to treat the right patient with the right indication to avoid unnecessary complications.
Ethics Committee Approval: Ethical approval for this study was obtained from Dicle University Hospital Medical Faculty Ethics Committee (Approval Number: 318, date: 03.09.2020).
Informed Consent: An informed consent was obtained from all the patients.
Publication: The results of the study were not published in full or in part in form of abstracts.
Peer-review: Externally peer-reviewed.
Authorship Contributions: Any contribution was not made by any individual not listed as an author. Concept – M.A, M.D.; Design – M.A, M.D.; Supervision – M.A, M.D.; Resources – M.A, M.D.; Materials – M.A, M.D.; Data Collection and/or Processing – M.A, M.D.; Analysis and/or Interpretation – M.A, M.D.; Literature Search – M.A, M.D.; Writing Manuscript – M.A, M.D.; Critical Review – M.A, M.D.
Conflict of Interest: The authors declare that they have no conflicts of interest.
Financial Disclosure: The authors state that they have not received any funding.
1) Fournier JA. Jean-Alfred Fournier 1832-1914. Gangrène
foudroyante de la verge (overwhelming gangrene). Sem
Med 1883. Dis Colon Rectum. 1988;31(12):984-988.
https://doi.org/10.1007/BF02554904
2) Sorensen MD, Krieger JN, Rivara FP, Broghammer
JA, Klein MB, Mack CD, et al. Fournier"s Gangrene:
population based epidemiology and outcomes. J Urol.
2009;181(5):2120–6.
https://doi.org/10.1016/j.juro.2009.01.034
3) Lewis GD, Majeed M, Olang CA, Patel A, Gorantla VR,
Davis N, et al. Fournier"s Gangrene Diagnosis and Treatment:
A Systematic Review. Cureus. 2021;13(10):e18948.
https://doi.org/10.7759/cureus.18948
4) Fernando SM, Tran A, Cheng W, Rochwerg B,
Kyeremanteng K, Seely AJE, et al. Necrotizing Soft Tissue
Infection: Diagnostic Accuracy of Physical Examination,
Imaging, and LRINEC Score: A Systematic Review and
Meta-Analysis. Ann Surg. 2019;269(1):58–65.
https://doi.org/10.1097/SLA.0000000000002774
5) Chennamsetty A, Khourdaji I, Burks F, Killinger KA.
Contemporary diagnosis and management of Fournier"s
gangrene. Ther Adv Urol. 2015;7(4):203–15.
https://doi.org/10.1177/1756287215584740
6) Mallikarjuna MN, Vijayakumar A, Patil VS, Shivswamy
BS. Fournier"s Gangrene: Current Practices. ISRN Surg.
2012;2012:942437.
https://doi.org/10.5402/2012/942437
7) Chander J, Stchigel AM, Alastruey-Izquierdo A, Jayant
M, Bala K, Rani H, et al. Fungal necrotizing fasciitis, an
emerging infectious disease caused by Apophysomyces
(Mucorales). Rev Iberoam Micol. 2015;32(2):93–8.
https://doi.org/10.1016/j.riam.2014.06.005
8) Argenta LC, Morykwas MJ. Vacuum-assisted closure: a new
method for wound control and treatment: clinical experience.
Ann Plast Surg. 1997;38(6):563–76; discussion 577.
https://pubmed.ncbi.nlm.nih.gov/9188971/
9) Singh A, Ahmed K, Aydin A, Khan MS, Dasgupta P.
Fournier"s gangrene. A clinical review. Arch Ital Urol
Androl. 2016;88(3):157–64.
https://doi.org/10.4081/aiua.2016.3.157
10) Pour SM. Use of Negative Pressure Wound Therapy With
Silver Base Dressing for Necrotizing Fasciitis. J Wound
Ostomy Continence Nurs. 2011;38(4):449–52.
https://doi.org/10.1097/WON.0b013e31821e43f1
11) Eke N. Fournier"s gangrene: a review of 1726 cases. Br J
Surg. 2000;87(6):718–28.
https://doi.org/10.1046/j.1365-2168.2000.01497.x
12) Weinfeld AB, Kelley P, Yuksel E, Tiwari P, Hsu P, Choo J,
et al. Circumferential negative-pressure dressing (VAC) to
bolster skin grafts in the reconstruction of the penile shaft
and scrotum. Ann Plast Surg. 2005;54(2):178–83.
https://doi.org/10.1097/01.sap.0000143606.39693.3f
13) Morykwas MJ, Argenta LC, Shelton-Brown EI, McGuirt
W. Vacuum-assisted closure: a new method for wound
control and treatment: animal studies and basic foundation.
Ann Plast Surg. 1997;38(6):553–62.
https://doi.org/10.1097/00000637-199706000-00001
14) Assenza M, Cozza V, Sacco E, Clementi I, Tarantino
B, Passafiume F, et al. VAC (Vacuum Assisted Closure)
treatment in Fournier"s gangrene: personal experience and
literature review. Clin Ter. 2011;162(1):e1-5
15) Czymek R, Schmidt A, Eckmann C, Bouchard R, Wulff
B, Laubert T, et al. Fournier"s gangrene: vacuum-assisted
closure versus conventional dressings. Am J Surg.
2009;197(2):168–76.
https://doi.org/10.1016/j.amjsurg.2008.07.053
16) Yanaral F, Balci C, Ozgor F, Simsek A, Onuk O, Aydin M,
et al. Comparison of conventional dressings and vacuumassisted
closure in the wound therapy of Fournier"s
gangrene. Arch Ital Urol Androl. 2017;89(3):208–11.
https://doi.org/10.4081/aiua.2017.3.208.
17) Ozturk E, Ozguc H, Yilmazlar T. The use of vacuum
assisted closure therapy in the management of Fournier"s
gangrene. Am J Surg. 2009;197(5):660–5; discussion 665.
https://doi.org/10.1016/j.amjsurg.2008.04.018
18) Radcliffe RS, Khan MA. Mortality associated with
Fournier"s gangrene remains unchanged over 25 years.
BJU Int. 2020;125(4):610–6.
https://doi.org/10.1111/bju.14998
19) Atakan IH, Kaplan M, Kaya E, Aktoz T, Inci O. A lifethreatening
infection: Fournier"s gangrene. Int Urol
Nephrol. 2002;34(3):387–92.
https://doi.org/10.1023/a:1024427418743
20) Ghnnam WM. Fournier"s gangrene in Mansoura Egypt: a
review of 74 cases. J Postgrad Med. 2008;54(2):106–9.
https://doi.org/10.4103/0022-3859.40776
21) Nisbet AA, Thompson IM. Impact of diabetes mellitus
on the presentation and outcomes of Fournier"s gangrene.
Urology. 2002;60(5):775–9.
https://doi.org/10.1016/s0090-4295(02)01951-9
22) Chen CS, Liu KL, Chen HW, Chou CC, Chuang CK,
Chu SH. Prognostic factors and strategy of treatment
in Fournier"s gangrene: a 12-year retrospective study.
Changgeng Yi Xue Za Zhi. 1999;22(1):31–6.
https://pubmed.ncbi.nlm.nih.gov/10418207/
23) Korkut M, Içöz G, Dayangaç M, Akgün E, Yeniay L,
Erdoğan O, et al. Outcome analysis in patients with
Fournier"s gangrene: report of 45 cases. Dis Colon Rectum
2003;46(5):649–52.
https://doi.org/10.1007/s10350-004-6626-x
24) Kızılay F, Akıncıoğlu E, Semerci B, Altay B. Comparison
of Vacuum Assisted Closure and Conventional Dressing
in Fournier Gangrene Treatment. The New Journal of
Urology. 2019:14(1)18–25.
https://doi.org/10.33719/yud.531642
25) Ozkan OF, Koksal N, Altinli E, Celik A, Uzun MA,
Cıkman O, et al. Fournier"s gangrene current approaches.
Int Wound J. 2016;13(5):713–6.
https://doi.org/10.1111/iwj.12357
26) Estrada O, Martinez I, Del Bas M, Salvans S, Hidalgo
LA. Rectal diversion without colostomy in Fournier"s
gangrene. Tech Coloproctol. 2009;13(2):157–9.
https://doi.org/10.1007/s10151-009-0474-6
27) Morua AG, Lopez JAA, Garcia JDG, Montelongo RM,
Guerra LSG. Fournier"s gangrene: our experience in
5 years, bibliographic review and assessment of the
Fournier"s gangrene severity index. Arch Esp Urol.
2009;62(7):532–40.
https://pubmed.ncbi.nlm.nih.gov/19815967/
28) Laor E, Palmer LS, Tolia BM, Reid RE, Winter HI.
Outcome prediction in patients with Fournier"s gangrene.
J Urol. 1995;154(1):89–92.
https://pubmed.ncbi.nlm.nih.gov/7776464/
29) Corcoran AT, Smaldone MC, Gibbons EP, Walsh TJ, Davies
BJ. Validation of the Fournier"s gangrene severity index in
a large contemporary series. J Urol. 2008;180(3):944–8.
https://doi.org/10.1016/j.juro.2008.05.021
30) Kutsal C, Baloglu IH, Turkmen N, Haciosmanoglu T,
Albayrak AT, Cekmece AE, et al. What Has Changed
in the History of Fournier"s Gangrene Treatment: The
Single Center Experience. Sisli Etfal Hastan Tip Bul.
2023;57(1):99-104.
https://doi.org/10.14744/SEMB.2023.90757